Axion BioSystems and Agilent Technologies Resolve Litigation

ATLANTA--(BUSINESS WIRE)-- Axion BioSystems, Inc., a leading provider of live-cell analysis technologies, today announced that Agilent Technologies, Inc. and Axion BioSystems have fully resolved the issues in the two lawsuits between them, pending in the United States District Court for the District of Delaware, pursuant to the terms of a confidential settlement agreement.

Neither party has admitted liability for the other party’s claims or counterclaims or otherwise agreed to the positions asserted as a condition of the resolution of these two lawsuits. Axion continues to stand firmly behind its technology, intellectual property, and business practices.

“We are pleased to have resolved this matter and to move forward without any impact on our products or business,” said Julien Bradley, Chief Executive Officer at Axion BioSystems. “Axion will continue, as we always have, to innovate our technology while respecting others’ intellectual property and ensuring that our customers always have access to the very best tools for critical healthcare research notwithstanding the impact this may have on incumbents in our marketplace.”

Axion BioSystems will continue to market, manufacture, and sell its existing line of products and looks forward to developing new products that will continue to evolve to meet its customers’ needs.

About Axion BioSystems

Axion BioSystems, Inc., headquartered in Atlanta, Georgia, USA, is a leading life science company focused on next-generation live-cell analysis tools for biomedical research and drug discovery. With innovative systems that monitor complex cellular activity in real time without disturbing the underlying biology, Axion’s technology accelerates scientific discovery with streamlined workflows providing more complete datasets. www.axionbiosystems.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421984149/en/

Victoria Stahl
Vice President Marketing, Axion BioSystems
[email protected]

Source: Axion BioSystems, Inc.

You May Also Be Interested In

• ComEd Reaches 99% Restoration Following Multi-Day Severe Storm Event
• Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
• Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026